Regeneron Pharmaceuticals Inc.
Large Cap · Healthcare · Biotechnology
$810.24+$4.31 (+0.53%)
Regeneron Pharmaceuticals Inc.
Large Cap · Healthcare · Biotechnology
$810.24+$4.31 (+0.53%)
Stock analysis
Get the AI take on REGN
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$541.00
High$821.11
Today $810.24
RSI (14)
90.8Overbought
03070100
Overall score
64/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$641
Median target
$808.57
Current price
$810.24
Highest
$1,030
LowHigh
Operating Record
Revenue
What's working
- Cash exceeds debt by $15.1B, leaving a net cash buffer, a good sign.
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
What the market charges
Forward P/E
Favorable · 36% below avg
13.20x
Price / sales
Reasonable · Priced reasonably against its revenue
5.16x
Price / FCF
Reasonable · Priced a bit rich against its cash flow
21.34x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
13.85x
How efficiently it compounds
ROIC
Reasonable · A middling return on the capital it puts to work
13.5%
ROE
Middle ground · Mixed
14.0%
Debt / equity
Favorable · 0.09 - strong leverage
0.09x
Current ratio
Strong · Comfortable room to cover bills due within a year
3.34x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $82.72B | 19.9 | +9.3% | 64 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |